Achieve Life Sciences Bolsters Board with Specialty Pharma Veterans Ahead of Key NDA Resubmission
Event summary
- Achieve Life Sciences appointed Jeffrey Farrow and Reid Waldman, MD to its Board of Directors on June 2, 2026.
- Farrow is CFO and Chief Strategy Officer of Tarsus Pharmaceuticals, with experience in three commercial launches and acquisitions totaling over $9 billion.
- Waldman is Founder and CEO of Veradermics, which raised $766.8 million in equity financings in 2026.
- Achieve is preparing for cytisinicline’s NDA resubmission and potential commercial launch as a smoking cessation treatment.
The big picture
Achieve’s board additions signal a strategic pivot toward commercialization as it nears a critical regulatory inflection point. The appointments of Farrow and Waldman bring deep expertise in launching specialty pharmaceuticals and navigating capital markets, addressing key gaps as Achieve prepares for cytisinicline’s NDA resubmission. The move underscores the company’s focus on transforming from a development-stage biopharma into a commercial player in nicotine dependence treatment.
What we're watching
- Launch Readiness
- How Achieve’s new board members will shape its commercial strategy ahead of cytisinicline’s potential approval.
- Regulatory Momentum
- The pace at which Achieve can navigate the NDA resubmission process following its Breakthrough Therapy designation.
- Market Positioning
- Whether Achieve can differentiate cytisinicline in a crowded smoking cessation market with no new prescription options in two decades.